Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial - Poll - MDSpire

Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial

Phase 3 results show fenebrutinib matched OCREVUS on disability progression in PPMS

February 17, 2026
3 min

The Medicine Maker

Share

Original Source(s)

The Medicine Maker

Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial

February 17, 2026

Related Content

Bmc Neurology

The Relationship Between Employment and Self-Reported Health Among Individuals with Multiple Sclerosis in Sweden

by Alejandra Machado, Jessica Dervish, Emilie Friberg
March 11, 2026

European Radiology

Rule-based semi-automated method to segment black hole multiple sclerosis lesions on post-gadolinium 2D T1-weighted brain images

Annals Of Neurology

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes